Molecular analysis and therapeutic targeting of PI3K signaling in thyroid cancer

Project: Research project

Project Details

Description

Approximately 2,000 patients with thyroid cancer die each year in the U.S., and many more suffer from progressive, symptomatic disease. The limited number of advanced thyroid cancer patients has been a major obstacle to our understanding of the molecular mechanisms involved in disease progression, as well as to the development of effective therapies. Furthermore, even when the driving oncogenic insults are known and targeted inhibitors are available, cancers invariably develop resistance to them. In this application, we leverage the power of mouse genetics and in vivo disease modeling to characterize novel pathways that are critical for thyroid cancer development and to define novel paradigms for rationally designed combinatorial therapies. Successful completion of the proposed studies will help map novel signaling pathways and design effective therapies, providing benefit not only to advanced thyroid cancer patients, but also to those with other tumor types sharing the same genetic alterations.
StatusActive
Effective start/end date2/1/0911/30/22

Funding

  • National Cancer Institute: $169,867.00
  • National Cancer Institute: $314,070.00
  • National Cancer Institute: $344,450.00
  • National Cancer Institute: $226,758.00
  • National Cancer Institute: $401,384.00
  • National Cancer Institute: $102,705.00
  • National Cancer Institute: $344,450.00
  • National Cancer Institute: $334,117.00
  • National Cancer Institute: $334,117.00
  • National Cancer Institute: $380,261.00

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.